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Abstract
In the two decades after 1990, the rates of child and maternal mortality dropped by over 40% and 47%, respectively.
Despite these improvements, which are in part due to increased access to medical technologies, profound health dis-
parities exist. In 2015, a child born in a developing region is nearly eight times as likely to die before the age of 5 than one
born in a developed region and developing regions accounted for nearly 99% of the maternal deaths. Recent developments
in nanotechnology, however, have great potential to ameliorate these and other health disparities by providing new cost-
effective solutions for diagnosis or treatment of a variety of medical conditions. Affordability is only one of the several
challenges that will need to be met to translate new ideas into a medical product that addresses a global health need. This
article aims to describe some of the other challenges that will be faced by nanotechnologists who seek to make an impact
in low-resource settings across the globe.
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Introduction
Recent analysis of data derived from the Global Burden of
Disease Report1–13 indicated that globally, life expectancy
increased by more than 11 years during the period from
1970 to 2010.14 This improvement was largely driven by
profound reductions in child mortality (>60%) and adult
female mortality (>40%), with lower reductions in adult
male mortality that varied widely by age group (15%–
35%).14,15 Throughout this 40-year period, however, the
life expectancy of a person born in one of the world’s
poorer countries was consistently more than 30 years
shorter than that of a person born in one of the wealthiest.14
In much of the world, the burden of preventable and trea-
table diseases is still staggering and poses formidable chal-
lenges for health-care systems. In 2015, nearly six million
children under the age of 5 died16 due to preventable and
treatable diseases such as diarrhea (nearly 600,000 in 2013)
or malaria (over 450,000 in 2013).16 In 2015, more than
800 women died each day due to complications in child-
birth.5 Notably, the contribution of noncommunicable dis-
eases, such as heart disease and diabetes, to the global
burden of disease rose from 43% to 54% between 1990 and
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2010.17 Collectively, these data indicate that there remains
a great need for improvements in healthcare. There exists
an urgent and persistent need to improve maternal and child
health, along with an evolving landscape with a growing
worldwide need to prevent, diagnose, monitor, and treat
noncommunicable diseases.18,19 Perhaps most importantly,
these data point to persistence in health disparities, with a
disproportionate burden of disease on the poorest individ-
uals in the world’s poorest countries.20–24 Finally, there is a
growing concern that over the next few decades climate
change will strongly affect population health, with the
greatest impact being that of infectious diseases on people
with few resources to prevent, diagnose, or treat such
diseases.25,26
Hence, in this era, there are four defining features of the
global health landscape: (i) a lingering need to treat and
eradicate infectious diseases, (ii) a growing need to address
health issues related to noncommunicable diseases,19,27,28
(iii) the persistence of profound health disparities,20,22–24
and (iv) the ongoing effects of climate change.25,26 The
success of the ongoing and emerging efforts to improve
global health will depend strongly on the ability of medical
technology developers to innovate new and affordable
products and deliver them to the marketplace.
A number of emerging technologies hold great potential
to address these global health needs. In particular, the con-
vergence of developments in nanotechnology, mobile tech-
nology, and information technology is enabling
development of (i) affordable laboratory or point-of-care
diagnostics,9,10,12,29–41 (ii) remote clinic, home-based ther-
apeutics, or technology for prevention,31,42–46 (iii)
improved communication with patients and across health-
care facilities,47–49 and (iv) technology for broad-based
health surveillance.50,51 These approaches, some of which
are highlighted in this special issue,52,53 may be able to
effectively leverage cost reductions driven by consumer
technologies. While these emerging technologies hold
great promise, efforts to commercialize and successfully
deploy new medical technology are certain to face a num-
ber of challenges, especially in the areas of greatest need.
This article describes the types of challenges that might
be faced in the development and deployment of nanotech-
nology to improve health care in low-resource settings.
These include a set of challenges that would be faced in
any health-care technology venture and others that may be
unique to deployment in low-resource settings. In addition,
we provide a sampling of innovative strategies and
approaches that could support nanotechnology ventures.
In medical nanotechnology, as in other fields, the greatest
opportunities lie in the areas of greatest need. The broad
array of emerging nanotechnologies and their potential for
addressing clinical issues in global health have been
described in other recent reviews.37,44–46,54–62 This review
aims to motivate nanotechnologists to seek out opportuni-
ties in the areas of greatest need and to enable them to
identify and directly address the challenges faced in
translating lab-based success into clinical impact in low-
resource settings.
Challenges
Emerging technologies offer an array of opportunities to
address critical issues in global health, but a variety of
challenges may be faced in the pursuit of successful
deployment of a new medical product. Technical chal-
lenges must be overcome to generate new knowledge
and/or produce new technology; market-related challenges
must be addressed to appropriately target the product for
the market conditions; human resource–related challenges
must be overcome to match human resource demands with
capacity; and finally, a range of logistical challenges must
be met to manufacture and deliver the product. Each of
these four categories of challenges is described in the fol-
lowing sections. Embedded within each of these four cate-
gories are specific infrastructure-related challenges that
arise due to the lack of high-quality infrastructure for busi-
ness and medical care delivery in low-resource settings.
Technical challenges
Recent advancements in technology have enabled
improved device versatility and functionality in a wide
variety of scenarios. This is mainly the result of advanced
material properties, miniaturization, and overall robust-
ness of the end products. However promising, many
devices fail to meet the challenges imposed by extreme
environmental conditions or shortcomings in the health-
care infrastructure.
In many low-resource settings, the physical environment
can present extreme demands on the ability of technology
to function properly. Most notably, the technology must be
able to function in the presence of humidity, temperature,
and/or dust.32,63 The climatic conditions in some low-
resource settings may reach temperature and/or humidity
levels outside the range of typical technical specifications.
For example, the temperatures in Mali or Pakistan can
reach as high as 45C; in Mongolia or northern Alaska as
low as 30C; and the humidity in the rain forest of Brazil,
the Democratic Republic of the Congo, or Papua New Gui-
nea can be consistently above 80%. During the summer of
2015, the combination of high temperature and humidity
put the heat index at 74C in parts of Iraq, where air-
conditioning is not widely used and electricity and refrig-
eration are unreliable. One study that monitored conditions
along the supply chain in four different countries found that
samples of rapid diagnostic tests were regularly exposed to
temperatures and humidity levels that far exceeded general
guidelines for pharmaceuticals. However, due to fact that
the specific tests were designed to withstand high heat and
humidity, they were only rarely exposed to conditions that
exceeded the manufacturers’ guidelines.64 Such studies
underscore the importance of designing technology with
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the ability to withstand conditions that might be experi-
enced in such settings. In the desert and in the tropics, the
high levels of moisture, dust, and/or other contaminants
can push the limits of the core principles that underlie the
operation of a certain class of technologies or may place
additional demands on the engineering design of a spe-
cific device.
In addition to the extremes of climatic conditions, the
medical product may also have to survive and function
properly in conditions that are not well controlled. On-
site and in-transit refrigeration or humidity control may
be nonexistent or at best, unreliable.9,32 The levels of dust
or contaminants in the clinic, clinical laboratory facility, or
at home may be similar to those experienced in the external
environment. In a recent visit to a newly constructed hospital
in a capital city in sub-Saharan Africa, it was disturbing to
note that the only ventilation in the clinical laboratory facil-
ities was provided through open windows, which invited the
dust and grime of a rapidly developing metropolis. The
designers of the imported benchtop technology to analyze
blood or urine samples may not have envisioned their device
operating under such conditions, but the validity of the mea-
surements and ultimately patient safety depend on the ability
of the technology to function properly in the presence of a
substantial amount of airborne pollutants.
A number of recent technological advancements have
been implemented to address or sidestep known challenges
such as refrigeration. These point-of-care tests avoid the
need for refrigeration through the use of dry reagents9,65
and vaccine technologies, such as vaccines with improved
temperature stability and vaccine vial monitors—that use
temperature-sensitive dyes to indicate if a vaccine has been
exposed to temperatures that would render it ineffective.66
Market-related challenges
With any medical technology, the question of “who are you
marketing to”? can be important to consider at an early stage
of technology development. The decision to purchase a med-
ical product may be made by national authorities, insurance
providers, hospitals or clinics, health-care providers, or by
individual users.10,11,67 Although the critical factors in the
decision-making process may primarily be that of documen-
ted performance in randomized clinical trials, other factors
may also play a role, such as cost, brand recognition, brand
loyalty, personal contacts, or individual preferences.
In low-resource settings, the question of who are you
marketing to? may also be influenced by a number of other
factors. For large-scale efforts to reduce mortality due to
infectious disease, the dominant purchaser of medical prod-
ucts may be United Nations (UN) agencies (e.g. United
Nations International Children’s Emergency Fund (UNI-
CEF), United Nations Development Programme (UNDP),
United Nations Population Fund (UNFPA)); major interna-
tional not-for-profit aid agencies (e.g. Bill and Melinda
Gates Foundation, Cooperative for Assistance and Relief
Everywhere (CARE), Doctors Without Borders, Oxfam);
or governmental international aid organizations (e.g.
United States Agency for International Development
(USAID), Department for International Development
(DFID)). For many developers of medical products, a sin-
gle contract with one of these organizations can not only
provide an initial boost in sales and capital but it can often
lead to a stable influx of major contracts from other insti-
tutions or governments due to the visibility and high degree
of respect afforded to these organizations.
Acquisition of a major contract with a nationalized
health-care system will necessitate successful integration
into their procurement system.68 This may require registra-
tion, documentation, price negotiation, and several levels
of approval through processes that can be opaque
and byzantine.69 As with many of these challenges, a
well-informed local contact who has experience with the
processes can be a very valuable asset to the business
development team.
Some medical nanotechnologies may be directly mar-
keted to the consumer, which would place a different set of
demands on pricing and distribution strategies. Most
importantly, however, selling directly to the consumer in
low-resource settings presents a multifaceted challenge to
marketing. The lack of telecommunications infrastructure,
poor literacy rates, brand loyalty, and aversion to innova-
tion can all limit the ability to reach and penetrate new
markets.
Many technology developers are required to put forth
great efforts to protect intellectual property even when
manufacturing, production, and sales all take place within
one country. International considerations drastically
increase the cost, effort, and expertise required for patent
protection.12,33,43,67 These concerns may be heightened in
many low-income countries that may not have well-
established patent regulations or enforcement capabilities.
In some instances, countries have formed regional organi-
zations (e.g. Africa Regional Intellectual Property Organi-
zation) to pool resources and simplify procedures for
inventors to obtain patent protection across a region. A
related concern for many producers is the growing preva-
lence of counterfeit medical products.11,67,70 This has huge
implications for the pharmaceutical industry—both in terms
of patient safety and commercial competitiveness. Multia-
gency, multinational efforts are underway to reduce the
impact of such products, and the affected industries are essen-
tial partners in preventing such crimes.11,67,70 Some efforts
are focused on the development of affordable and simple-to-
use technologies that can be used at the point of administra-
tion, to detect counterfeit medicines.70,71 For medical
devices, a design that incorporates security and traceability
features to increase the difficulty for counterfeit production
may greatly facilitate anti-counterfeiting enforcement.
A final market-related challenge is that of interdepen-
dence. Many technologies address only one step in a com-
plex multistep process required for clinical success. The
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simplest and most widespread example may be the inter-
dependence of diagnosis and treatment. The least expen-
sive and simplest technology for diagnosis would be
useless without an ability to treat and vice versa. Further-
more, the value of any diagnostic may be lost in an envi-
ronment where treatment is available, inexpensive, and has
historically been widely utilized. For example, one exten-
sive clinical trial demonstrated that an inexpensive rapid
diagnostic test for malaria could accurately produce a pos-
itive or negative test result, but the treatment was still
highly prescribed after a negative test result due to the
expectations of the patient and caution on the part of the
clinician.72 Other studies have also documented a reluc-
tance to accept negative test results by both patients and
health-care workers.73 While there have been successful
demonstrations of the positive impact of rapid diagnostic
tests on treatment decisions,74 this interdependence is com-
plex and may require a comprehensive integration of new
technologies into the clinic environment.
Human resource challenges
In areas that have limited access to medical products, there
is often a scarcity of trained and credentialed medical per-
sonnel. The shortage of health-care workers is most severe
in many countries in sub-Saharan Africa, the Indian sub-
continent, and Southeast Asia.75 For example, it has been
reported that sub-Saharan Africa has 10% of the world’s
population and 25% of the world’s burden of disease, yet
only has 1% of the world’s health-care workers.76 This
paucity of suitably trained personnel may be the most sig-
nificant of all of the infrastructure-related challenges.
The notion of task shifting is the redistribution of tasks
from a highly trained individual (such as a physician) to
someone with less training, such as a nurse or a health-care
worker who has received specific training for limited num-
ber of tasks.77,78 Task shifting may help to reduce health-
care costs in any setting but may have its greatest impact in
low-resource settings that have a shortage of trained health-
care workers.9,63,75 Although there are only a handful of
randomized clinical trials that have investigated the
effects of task shifting, there is some evidence indicating
that the practice can be effective in improving health
outcomes.79–81 For technology developers, explicitly
designing a technology that enables task shifting
may greatly increase the likelihood that it could be widely
adopted and used effectively in a variety of settings. For-
tunately, the nature of many nanotechnologies and their
application in rapid diagnostics are extremely well suited
to enable task shifting and their eventual success may be
primarily or entirely due to the fact that they can be readily
and reliably administered by health-care workers with lim-
ited training. Developers should keep in mind, however,
that specific aspects of procedures could have a profound
impact on adoption and eventual efficacy when used in the
field. For example, one study that investigated three
different rapid diagnostic test kits for cholera demonstrated
that two of the systems performed equivalently when used
by a laboratory technician or when task shifted to a com-
munity health worker, but the third system did not perform
as well in the hands of community health workers.82
Design for ease-of-use is a core principle of engineering
design practices that is recommended for any technology in
any setting. However, ease-of-use often involves trade-offs
with versatility and the balance of the scale may be differ-
ent in low-resource settings than in a state-of-the-art health
facility. For example, in a well-staffed, well-funded state-
of-the-art facility, it might be preferable to purchase a
device that has the versatility to be used on infants as well
as adults but requires careful adjustments or to purchase a
multifunctional device that can perform a battery of diag-
nostics but requires more reagents and more careful and
sophisticated interpretation of results. In low-resource set-
tings, the need for ease-of-use might tip the scales in the
other direction where simple procedures for administration
and interpretation may be preferred.
An important aspect of design for ease-of-use is to avoid
or minimize the need for technology-specific training. Inte-
gration of new technology is more likely to be successful
when its functionality is similar to those routinely used by
health-care workers. In some cases, however, it may be
necessary to develop and deliver programs to train users
in the appropriate use of a device. Minimizing the need for
technology-specific training can greatly improve the like-
lihood of success and widespread use of a new medical
technology.
Design for ease-of-maintenance-and-repair is an impor-
tant adjunct to design for ease-of-use. Many medical tech-
nologies require the services of clinical engineers and/or
biomedical engineering technicians (BMETs) to ensure
proper use.32,83–85 The clinical engineering team is respon-
sible for all aspects of health technology management: (i)
checking technical specifications, (ii) recommending spe-
cific products for procurement, (iii) configuring the device,
(iv) training clinical staff in its use, (v) communicating with
the manufacturer, (vi) establishing test and maintenance
protocols, (vii) scheduling its use to optimize availability,
(viii) maintaining a suitable supply of consumables, (ix)
device replacement, and (x) eventual decommission-
ing.84,85 The BMET is responsible for performing routine
maintenance and repairs, which is often sufficient to keep
critical equipment in condition for safe and reliable opera-
tion. However, some manufacturers require that mainte-
nance and repairs be performed by a technician employed
by the manufacturer or by an independent technician who
has specific certification on that device. Violation of this
requirement could invalidate a warranty on a substantial
capital investment. Such policies are usually imposed to
ensure continued safe operation of the device but are a clear
deterrent to purchase and/or use in low-resource settings.
Since many clinics in low-resource settings have severe
shortages in suitably trained clinical engineers and BMET
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staff, this produces another level of human resource chal-
lenges. Given these shortages, technology developers could
greatly facilitate the adoption and long-term successful
deployment of their products if they designed to reduce
demands on the technical staff in the clinic. This could
include a clear demonstration of compliance with published
technical specifications; simple procedures for setup, con-
figuration, use, and decommissioning; and clear and
straightforward procedures for safe maintenance and repair
(of at least the most common problems) by a locally based
BMET without device-specific training.
Of course, addressing any or all of these challenges
could introduce trade-offs with cost that might prove to
be devastating for sales. A simple injection system can
simplify the prophylactic administration of a drug to reduce
postpartum hemorrhage in a manner that enables task shift-
ing to a community health worker.86 However, although
seemingly inexpensive (*US$1 per dose), this successful
example of task shifting, design for ease-of-use, and design
for ease-of-maintenance-and-repair increased the per-dose
cost enough to severely limit adoption and use.80
Successful deployment of many medical technologies
requires the expertise of several individuals in addition to
that of the health-care worker performing the procedure
and the clinical/biomedical engineering team. These may
include in-country sales and distribution teams, procure-
ment specialists, and experts to train customers in the use
of the technology. Assembling the cohort of people with
the requisite expertise and resources may be particularly
challenging in low-resource settings.
Logistical challenges
Perhaps the most daunting and unpredictable set of chal-
lenges can be grouped together as “logistics.” Collectively,
these factors can contribute greatly to the depth and width
of the valley of death.11 Many of the design decisions that
are made early in the product development process can
have a profound impact on the team’s ability to success-
fully meet these logistical challenges. For this reason, it is
very advantageous—perhaps essential—for technology
developers to at least consider these issues, as they traverse
the stages of technical development.33 When planning for
deployment in low-resource settings, each of these chal-
lenges can be amplified by limitations in the business infra-
structure—especially in the health-care sector.
The first of these challenges is that of field testing,33,87
or testing in the target environment. These initial trials can
profoundly impact the product development process and
can provide powerful data to help justify the substantial
investments that will be required to bring a product to the
market. An effective plan for field testing might include
several rounds of tests to evaluate initial prototypes, con-
firm product relevance in terms of environmental and cul-
tural acceptance, evaluate the level of difficulty for product
application compliance by individuals with little or no
training, validate performance of the final design, and to
demonstrate efficacy in the target environment.33 Even
when initial field tests have shown positive results, lack
of field testing to establish operational guidelines could
substantially slow the adoption of new technology, as has
been the case with a diagnostic test for human papilloma-
virus.80 Execution of a field trial may require approval of
an institutional review board and/or approval by local gov-
ernmental agencies. Planning and performance of the field
trial is likely to be greatly facilitated by a strong partnership
with local clinical contacts, government agencies, and pos-
sibly international organizations that are active in the area.
For most medical technologies, the process of obtaining
regulatory approval for sale and marketing can pose sub-
stantial, time-consuming, and expensive challenges.40 The
need for, or the type of, approval that will be required will
depend on the technology, its purpose and use, and the
country in which it will be deployed.67,88 The processes for
obtaining the Food and Drug Administration approval for
marketing in the United States are typically time consum-
ing and resource intensive but vary greatly depending on
the nature of the device, the perceived risk, and the exis-
tence of predicate devices. For use in low-resource settings
outside of the United States, approval by the regulatory
body of the country-of-use may be required. This process
may be simplified if the device has already been approved
for marketing in the United States or in Europe. For exam-
ple, in Ethiopia, the process can be greatly streamlined if
the product is already registered and marketed by members
of the International Conference on Harmonization of Tech-
nical Requirements for Registration of Pharmaceuticals for
Human Use.89 For many developers of nanotechnology or
other types of medical devices, the clinical need and target
markets are not restricted to a particular country or region
and therefore the process of obtaining regulatory approval
in each country of use can require a substantial investment
of time and resources. To streamline this multinational
approval process, the World Health Organization (WHO),
other international institutions, and many national regula-
tory agencies are actively promoting the harmonization of
regulations so that medical products can more rapidly and
efficiently reach the end user.67
The logistics involved in manufacturing present a set of
challenges that are strongly influenced by policies. For
example, medical products must be manufactured in a man-
ner that complies with specific standards.67 As with regu-
latory approval, the specific standards may depend upon
the nature of the product as well as the country-of-use.
Following the established trend with consumer products,
many medical products are now manufactured in China,
India, Brazil, and other countries. For the nanotechnologist
seeking to establish manufacturing capabilities, the most
straightforward option may be to keep manufacturing oper-
ations close to the home base of the R&D laboratory, but
this approach should be carefully considered in light of
alternative options. The primary advantages of setting up
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manufacturing facilities close to the research labs may
include ease of transfer of technologies and techniques,
ability to perform testing early and often during the
development of manufacturing processes, familiarity with
regulations and procedures, and open communication
between technologists, manufacturers, and business man-
agers. On the other hand, the primary advantages of
setting up manufacturing facilities overseas may be a
reduction in manufacturing costs, the ability to leverage
existing manufacturing capabilities and expertise, and
proximity to some of the larger target markets.
To distribute the product to the point of care in low-
resource settings, there are some challenges that are shared
across sectors. In the World Bank index of “Ease of Doing
Business,” only two countries in sub-Saharan Africa rank
in the top quartile (South Africa and Rwanda); approxi-
mately 70% of the countries in the region rank in the lowest
quartile.69 Other challenges in these regions may be unique
to the health sector.10 Upon arrival into the country-of-use,
import regulations and tariffs may be burdensome and
bureaucratic delays can be substantial and unpredictable.67
Transportation from the port-of-entry to the point-of-care
may require a variety of modes of transport, each of which
may present specific demands on coordination and han-
dling. Throughout the process, security of the product from
theft, destruction, or contamination must be assured. For
health-care products, there may be additional concerns if
the product utilizes controlled substances or if there is a
potential for misuse or off-market sales. Some newly devel-
oped products may be able to tap into existing distribution
channels and procedures, especially if they are being sold
to or administered by the national health-care system or by
a major nongovernmental organization (NGO). Other prod-
ucts may require the development of new distribution chan-
nels or modifications to the procedures that are in place. In
either situation, successful distribution usually requires a
partnership with informed local contacts that have the
authority and incentive to guide the creation and mainte-
nance of distribution channels and procedures.
As mentioned earlier, for medical products that require
refrigeration, the need for storage may present very specific
logistical challenges, most of which can be directly tied to
the reliability of the electrical grid or backup systems. Other
storage requirements may not be as obvious, such as the
inherent trade-offs between access and security. For a med-
ical product to be useful, the health-care worker must have
access to the device and any consumables at the time of
need. If the product is stored in a locked cabinet that is only
accessible to a supervisor, the product may be useless when
the supervisor is off duty or in a different part of the facility.
Alternatively, storage in a location that is accessible to a
large number of employees may result in depletion of stock
due to theft. Systems that enable traceability can greatly
expand access on the front lines without comprising security.
In considering the usability of a medical device, the
most obvious considerations are those of the user at the
point-of-care. The user must have the requisite skills and
training, and procedures should be fool proof and efficient.
To maximize efficiency, it might be advantageous to con-
sider integration with concomitant procedures that are
likely to be administered. A technological solution for diag-
nosis or treatment is more likely to be used effectively if it
can be (i) administered in a single dose, minimizing the
need for patient compliance,9,32 (ii) synchronized with an
existing checkup or treatment, (iii) useful without involv-
ing substantial preparation or planning,9 (iv) a shared pro-
cess (such as a blood draw) with other procedures,
performed during a single visit to the clinic,10 and (v) used
as a non- or minimally invasive procedure. Some of the less
obvious factors that could adversely affect the usability of a
medical product are the need for (i) planning (e.g. fasting
prior to a blood draw), (ii) preparation (e.g. heating or
mixing), (iii) teamwork (e.g. a procedure that requires one
person to attend to the technology while the other attends to
the patient),10 (iv) time-sensitive procedures,33 (v) custo-
mization (e.g. dosing or scaling based on age or body
weight), or (vi) calibration (establishing a reference to a
gold standard prior to use). Removing such obstacles in the
hectic environment of an outpatient clinic or overcrowded
hospital ward would ensure wider and more accurate use of
the medical technology.
Among clinical engineers, it is often cited that the cost
of purchasing a medical device is the “tip of the iceberg”
and represents only a small portion of the cost of owner-
ship.90,91 The up-front capital costs are often only a small
portion of what will be spent on installation, consumables,
maintenance, repairs, and decommissioning.83 For some
medical applications of nanotechnology, such as certain
rapid diagnostic systems, the design of the system might
completely eliminate many of these costs and the primary
cost factor would be that of consumables. For these sys-
tems, minimizing the cost of consumables minimizes the
cost of ownership; systems that require costly single-use
cartridges—especially those that must be provided by the
equipment manufacturer—may incur operational costs
that are prohibitively high. In addition, systems that use
handheld or benchtop units for measurements or adminis-
tration may require costly regular maintenance and repair
to ensure patient safety. For use in any setting, but particu-
larly in low-resource settings, it is advantageous to design a
system in a manner that minimizes the need for maintenance,
simplifies maintenance procedures, requires only standard
tools and parts to perform maintenance procedures, and has
built-in capability to verify proper execution of maintenance
procedures. In addition, the decommissioning of medical
equipment can incur substantial financial as well as environ-
ment costs.83 Finally, the cost of operation may not only
include the price, difficulties, and uncertainties of stocking
a suitable supply of nonexpired consumables but may also
include the costs for specialized handling (such as refrigera-
tion, mixing, or secure storage) and specialized procedures
for sample disposal.32
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The final logistical challenge in this list is that of post-
market surveillance and outcomes assessment. A system
that produces good results in a research lab, in a teaching
hospital, and then in a clinical trial may fail in everyday
use. Such failures can be due to poor product performance
in the field, a failure to follow usage protocols, poor storage
practices, use of expired samples or components, or simply
failure to use the product. Thorough postmarket surveil-
lance is challenging in any environment and will be partic-
ularly challenging in low-resource settings. Systems
designed to facilitate good record keeping or mobile
phone–based data collection36 could greatly enhance the
quality and quantity of postmarket surveillance in a manner
that will ultimately improve the efficacy of the device.
However, more data do not always add value and eHealth
or mobile phone–based solutions are themselves subject to
the same concerns about efficacy and cost-effectiveness in
real-world settings.92 Recent reviews point to the need for
more field-testing and more outcomes data.48,51,93,94
Addressing the multidimensional
challenge
In the design of medical technology, the most obvious and
immediate design objectives are to address an important
clinical need in an affordable manner. When targeted usage
is in low-resource settings, the design and development
teams will be faced with the array of challenges outlined
above. In most instances, it would be advantageous, if not
imperative, to identify those challenges and to work with
end users to address them head-on, early in the design and
development process.9,10 Such an undertaking would con-
stitute a multiobjective optimization problem that is riddled
with the uncertainties inherent in the technology, physiol-
ogy, international markets, regulations, procurement poli-
cies, human factors, and cross-cultural dynamics.
Achieving the optimal design may not be possible or fea-
sible, but the likelihood of substantial clinical impact can
be greatly increased by attending to the array of challenges
and designing to achieve the characteristics outlined in
Figure 1 that are specifically identified by the end user or
are highly relevant to the targeted application.
Promising trends and innovative
approaches to translation
The challenges described above can be intimidating not
only because they are numerous and substantial but also
because they are interrelated. Some of these challenges
may have implications for the technical specifications and
technical design characteristics of the device; others may
have implications for the selection of a suitable business
model and/or for the composition of the business team.
Collectively, they emphasize the need for nanotechnolo-
gists to take a thoughtful and comprehensive approach to
product development and translation into low-resource
settings. In addition, these challenges highlight the further
need to recognize and plan early on in the venture in order
to facilitate efficient progress.
Although the mountain of challenges forebodes a long
and difficult climb, it is encouraging to note that there have
been many recent successes.80,95,96 In addition, a number of
new programs have been initiated that are designed to facil-
itate the process of developing and deploying technology in
low-resource settings. These include the Stanford-India Bio-
design Program,97 Rice 360,98 Engineering World Health,
and the IDEAS Program at Washington University School of
Medicine.99 Some emerging technologies show great prom-
ise, especially in the space that is at the intersection of nano-
technology and information technology.35,36,39 In addition to
the rapid advances in technology, there are also a number of
new initiatives and trends on the international development
landscape and innovative approaches to translation that
could accelerate the adoption and impact of new technolo-
gies in low-resource settings. Some of these promising
trends and innovative approaches to translation are briefly
discussed below.
•meets an important clinical need
•is low-cost
•considers local environmental and cultural factors
general characteristics
•minimal infrastructure demands (e.g. refrigeration)
•long shelf-life
•durable
•provides real-time results (diagnostics/therapy)





•simple to learn to use and simple to use
•facilitates task-shifting




•utilizes existing distribution channels
•straightforward, efficient deployment at point-of-care 
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Figure 1. Key design objectives in medical nanotechnology for
low-resource settings. Although the most obvious design objec-
tives are that the technology should meet an important clinical
need and it should be affordable by those that would use it, there
is a long list of other characteristics that are either necessary for,
or would greatly increase the likelihood of, successful translation
and widespread use in low-resource settings.
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Emerging economies and expanding markets
While the array of market challenges may be daunting,
there are many indications that new markets are emerging
and that the sizes of potential markets are increasing. Eco-
nomic development around the world has drastically
increased the purchasing capacity of a number of countries
and private individuals. In the year 2000, 57 countries were
classified by the World Bank as “low income”; by 2015, 21
of those countries had transitioned to “lower-middle
income,” 4 to “upper-middle income,” and 1 to “high
income.”100 These included several countries from South-
east Asia and sub-Saharan Africa. Such economic develop-
ment can result in improved markets for medical
technologies through increased public sector support for
national health programs and through increased purchasing
capacity in the private sector. The growth in the private
sector is primarily due to the increased demand for
health-care services by the growing middle class that will
be paid for by direct payment or through private insurance
carriers.
International initiatives
Since the turn of the century, a number of international
initiatives have been directed at improving lives by
increasing the intensity, efficacy, efficiency, and impact
of development activities. These initiatives have been
either directed or strongly supported by the United
Nations and have been the result of a coordinated effort
from a number of UN agencies, member state govern-
ments, and NGOs. For technologists interested in meeting
clinical needs in low-resource settings, such initiatives are
important because they can help to rally the international
community around specific technologies, to create or sta-
bilize markets, and to promote best practices that are tech-
nology based. Some of the most important of these
initiatives include
 Millennium Development Goals: At the UN Millen-
nium Declaration in the year 2000, world leaders
adopted a number of developments targets to be
achieved worldwide by the year 2015; these are now
known as the Millennium Development Goals
(MDGs). This list included several health-related
goals: most notably reduce child mortality (MDG
4); improve maternal health (MDG 5); and combat
HIV/AIDS, malaria, and other diseases (MDG 6).
For each goal, the Declaration adopted specific
metrics and targets. This Declaration provided a
framework for the development community and
governments that has been used to promote and
coordinate efforts to reach those goals. In 2016, it
is now clear that these goals have not yet been fully
achieved, but it is also clear that substantial progress
has been made.101
 Sustainable Development Goals: Over the past sev-
eral years, the post-2015 Development Agenda has
defined a framework that will serve to continue to
guide the development community beyond the MDG
era. At the 2015 UN Summit, world leaders adopted
a new set of goals that build upon the progress over
the previous 15 years and have a strong emphasis on
sustainability; these have been termed the Sustain-
able Development Goals (SDGs).102
 UN Commission on Life-Saving Commodities for
Women and Children (UNCoLSC)103: In 2012, the
UNCoLSC was established to promote and galva-
nize efforts to increase access for women and chil-
dren to critical medical products. The Commission
identified 13 affordable lifesaving commodities and
developed a set of recommendations for improving
their effectiveness and accessibility.
 Interagency list of medical devices for essential
interventions for reproductive, maternal, newborn,
and child health (RMNCH)104: Recently, a coordi-
nated effort by UNICEF, UNFPA, and WHO pro-
duced this comprehensive report,104 which aims to
strengthen health-care systems by identifying the
medical devices required to provide the essential
RMNCH interventions defined by existing WHO
guidelines and publications. Specifically, it provides
guidance for equipping various types of medical
facilities and information describing the needs for
medical equipment at each point in the continuum
of care in RMNCH.104
 Action Agenda from the Third International Confer-
ence on Financing for Development105: In Addis
Ababa in the summer of 2015, world leaders met
and committed to an agenda of investment and coop-
eration to promote development. The Action
Agenda includes a number of articles that specifi-
cally address public health, public health infrastruc-
ture, health product research and development,
human resource capacity, technology, innovation,
regulations, international trade, intellectual property
protection, multisector collaborations, and enhance-
ments to the business environment.105
For technology developers seeking to address critical
global health issues, these international initiatives and com-
mitments can help to define R&D targets, provide a frame-
work and opportunities for collaboration, and offer a strong
justification for financial support in proposals for grants or
investment.
Local production of medical products
in low-resource settings
In many countries, all or the majority of health-care equip-
ment and supplies are imported and acquired with funds
from one of two primary sources: (i) the national health
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programs—leading to depletion in foreign reserves and
contributing to unfavorable trade deficits or (ii) NGOs—
which provide donations through an unsustainable model.
There is a growing interest in reducing this dependence on
imported medical products by establishing and strengthen-
ing the local heath industry sector. Such initiatives to sup-
port “local production” are intended to simultaneously
improve health and promote economic development and
therefore they would address the core issues in the SDGs
in an integrated manner.
Recently, WHO has completed a set of studies to inves-
tigate the feasibility of local production of medical prod-
ucts in Sub-Saharan Africa.95,106–108 These studies identify
a broad array of challenges—most of which are those
described in the previous section of this report. Ventures
that pursue local production are likely to find an additional
set of challenges associated with manufacturing in low-
resources settings. These often include issues related to
supply chain, workforce, regulations, taxes, and so
on.107,108 The barriers to local production will vary across
countries and across regions, depending predominately
upon the nature of the medical product. For example, the
demands on infrastructure would be different for the pro-
duction of pharmaceuticals, consumables (e.g. gloves, syr-
inges, gowns), small medical devices (e.g. blood pressure
monitors, ultrasound probes), or larger medical devices
(e.g. X-ray machines). In addition to the infrastructure and
logistical issues, local production ventures might also con-
front obstacles to market penetration due to substantial bias
toward imported products, not only from potential end
users (such as clinicians or patients) but also from govern-
ment procurement agencies.67,95
Despite these challenges, there is considerable interest
in promoting local production, particularly in sub-Saharan
Africa95,105–109 because of the untapped potential for inno-
vation110 and because the possible benefits are so high—
both in terms of increased access to medical products and in
terms of economic development. In addition, there are
examples of success in Brazil, Russia, India, and
China,110–112 as well as in other countries such as South
Africa,113,114 Nigeria, and Jordan.115
For foreign technology developers, successful promo-
tion of local production could result in the creation of a
local competitor for an imported product, but only if the
local product could be used as a direct substitute for the
imported one. The most probable and substantial impacts of
efforts to develop local industry are likely to provide an
improvement in the business environment, favorable to
both domestic and foreign producers. Efforts to promote
local production could channel resources toward improve-
ments in physical and health-care infrastructure, increases
in quantity and quality of the healthcare workforce, simpli-
fication of regulatory policies and procedures, and
increased transparency in government procurement proce-
dures.95,108 Lastly, the development of a local health tech-
nology industry will produce potential partners for foreign
technology developers. Such partnerships may prove to be
the most efficient way to accelerate and amplify the impact
of new technologies.
Innovative partnerships
Recently, a number of partnerships between governmental,
nongovernmental, academic and for-profit institutions have
been developed to address a variety of issues related to the
shortage of access to medical products and quality health-
care.116–120 Such partnerships, some of which involve insti-
tutions from more than one country, are helping to address
the need for innovation that is highly focused on user
needs,33,117 shortages in human resources,117,118 the fail-
ures of distribution systems,116 and the obstacles in doing
business described in the previous section. The collective
impact of these partnerships may help to improve the envi-
ronment for emerging medical nanotechnologies. Perhaps
more importantly, some technology developers may be
able to join into existing partnerships or use them as models
for developing new ones.
In the specific realm of medical technology, several
partnerships have been established to address the shortages
in biomedical and clinical engineers, as well as BMETs.
One program, which is supported by the Fogarty Interna-
tional Centre, is directed at “Developing Innovative Inter-
disciplinary Biomedical Engineering Programs in Africa.”
This program provides training for biomedical engineers
and other medical and business professionals through a
partnership that involves Northwestern University (USA),
the University of Cape Town (South Africa), the University
of Ibadan and Lagos University (Nigeria), the University of
Bamako (Mali), and the University of Nairobi (Kenya). To
train BMETs, Engineering World Health, a US-based not-
for-profit organization, has partnered with Duke University
(USA) and several hospitals in Rwanda, Cambodia, Hon-
duras, Ghana, and Nigeria. A unique aspect of this exten-
sive program is that it includes a for-profit company,
General Electric, which provides financial support for the
training program.
The expanding and evolving landscape of partnerships
between private foundations, international organizations,
multinational corporations, government aid agencies, and
host governments has helped to expand or produce new
markets for medical products. Several broad-based partner-
ships are directed at increasing access to medical products
by shaping the economic landscape, coordinating R&D and
business development efforts, and supporting innovation in
technology, business, and government practices. For exam-
ple, to address the barriers faced in adopting a more effec-
tive treatment of severe malaria (injectable artesunate), the
Clinton Health Access Initiative partnered with UNITAID,
the United Kingdom’s DFID, Medicines for Malaria Ven-
ture, and the governments of Nigeria, Uganda, Cameroon,
Malawi, Kenya, and Zambia. One of the partners, UNI-
TAID, is itself a multinational organization with 29
Abbas et al. 9
member countries that is supported in large part through an
air ticket levies imposed in some member countries. Med-
ical technology developers may be able to greatly acceler-
ate testing, distribution, and adoption of their products by
tapping into such broad-based networks of partners.
An important feature for most, if not all, of these
efforts is that they strive to be true partnerships. This
emphasis on bidirectional exchange and collaboration is
part of a growing trend in development activities to shift
away from direct aid and to focus on partnership and
cross-sector collaboration to achieve sustainable devel-
opment.33,40,110,118,121–124 The growing emphasis on an
approach that values all partners as potential innovators
has perhaps never been as prominent as in the recent
2015 International Conference on Financing for
Development.105
Concluding remarks
The success of the persistent, and hopefully accelerating,
efforts to improve global health will depend strongly on the
ability of medical technology developers not only to inno-
vate new and affordable products but also to deliver them to
the marketplace. As a developer sets off to pursue these
goals, the challenges, as outlined in this review, will be
numerous and formidable.80 However, the confluence of a
number of factors—the growing base of science and engi-
neering knowledge to support new technological develop-
ments, the widespread availability of communication and
information technologies,47,125–127 the expanding array of
intersector and international partnerships,105,122 and the
emerging economies in many parts of the world—may work
to remove some of these obstacles and accelerate progress.
Technology developers may be able to increase their like-
lihood of success by identifying key trends in global health
and the global health community, by carefully characterizing
the multidimensional array of challenges specific to their
technology, and by adopting strategies for technology and
business development that maximize their ability to benefit
from ongoing trends as they work to address the complex set
of challenges on the path to clinical impact.
Readers considering deployment of nanotechnology in
global health are recommended to review specific case
studies.33,80,112 Suggested readings are also available on
specific topics, such as global burden of disease,13 human
resource capacity,76 task shifting,79 noncommunicable dis-
eases,19,28 and infectious diseases.54–62
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